Jasper Therapeutics (NASDAQ:JSPR) Shares to Reverse Split on Friday, November 6th

Jasper Therapeutics, Inc. (NASDAQ:JSPR)’s stock is scheduled to reverse split on Friday, November 6th. The 1-30 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, November 5th.

Jasper Therapeutics Stock Performance

Shares of Jasper Therapeutics stock traded up $0.03 during trading hours on Wednesday, reaching $0.51. The company’s stock had a trading volume of 767,002 shares, compared to its average volume of 795,539. The company has a market capitalization of $17.01 million, a P/E ratio of -0.32 and a beta of 3.30. The stock’s fifty day simple moving average is $0.59 and its two-hundred day simple moving average is $0.85. Jasper Therapeutics has a one year low of $0.32 and a one year high of $2.42.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.17. As a group, research analysts forecast that Jasper Therapeutics will post -0.94 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. HC Wainwright reissued a “buy” rating on shares of Jasper Therapeutics in a report on Tuesday, August 18th. William Blair initiated coverage on Jasper Therapeutics in a report on Wednesday, October 14th. They issued an “outperform” rating on the stock. Piper Sandler assumed coverage on Jasper Therapeutics in a report on Wednesday, August 12th. They set an “overweight” rating and a $2.00 price target for the company. Wall Street Zen raised Jasper Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $7.33.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ:JSPR) is a clinical-stage biotechnology company focused on developing therapies that target c-Kit (CD117), a protein found on hematopoietic stem cells and mast cells. The company is pursuing treatments intended to address diseases involving abnormal immune or blood-cell activity, as well as approaches that may improve preparation for hematopoietic stem-cell transplantation.

Jasper’s lead investigational product is briquilimab, formerly known as JSP191. Briquilimab is an anti-CD117 monoclonal antibody designed to deplete certain stem cells and mast cells.